Overview

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

Status:
Completed

Trial end date:
2004-05-01

Target enrollment:

Participant gender:

Summary

The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Pharma

Treatments:

Carbidopa
Carbidopa, levodopa drug combination
Levodopa